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X-ray crystallographya b s t r a c t
We present a study on the binding of gallic acid and its dimer ellagic acid to glycogen phosphorylase
(GP). Ellagic acid is a potent inhibitor with Kis of 13.4 and 7.5 lM, in contrast to gallic acid which
displays Kis of 1.7 and 3.9 mM for GPb and GPa, respectively. Both compounds are competitive inhi-
bitors with respect to the substrate, glucose-1-phoshate, and non-competitive to the allosteric acti-
vator, AMP. However, only ellagic acid functions with glucose in a strongly synergistic mode. The
crystal structures of the GPb-gallic acid and GPb-ellagic acid complexes were determined at high
resolution, revealing that both ligands bind to the inhibitor binding site of the enzyme and highlight
the structural basis for the signiﬁcant difference in their inhibitory potency.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction T state, low activity and substrate speciﬁcity) and GPa (phosphory-Glycogen phosphorylase (GP; E.C. 2.4.1.1) is the most well stud-
ied enzyme in glycogenmetabolism [1]. It catalyzes the ﬁrst step in
the intracellular degradation of glycogen to yield a-D-glucose
1-phosphate (Glc-1-P). Because of its central role in glucose home-
ostasis, GP has been exploited for the discovery of potent and
speciﬁc inhibitors [2–4] which may be used as antihyperglycaemic
agents. In the last decade, numerous studies have validated GP as a
pharmaceutical target for type 2 diabetes [5]. GP is an allosteric
enzyme that follows the MWC model [6]. It exists in two intercon-
vertible by phosphorylation forms: GPb (unphosphorylated,lated, R state, high activity and substrate speciﬁcity) [1]. GPb is a
homodimer with six distinct binding sites, the catalytic, the inhibi-
tor, the allosteric, the glycogen storage, the indole-binding and the
quercetin binding sites [1,7]. The molecular basis of the allosteric
transition from the T to R state lies with a ﬂexible loop (280s, resi-
dues 282–286) which in the T state partially blocks access to the
catalytic site. Upon transition from the T to R state, this loop
becomes disordered, allowing Arg569 to enter the catalytic site
and create the phosphate recognition site; that also provides
access for the substrate (glycogen) to reach the catalytic site [1].
The majority of the GP reported inhibitors are glucose deriva-
tives [2–4,8] that bind to the catalytic site and compete for binding
with the substrate. The catalytic site of GPb is buried at the center
of the protein molecule and it is accessible to the bulk solvent
through a 15 Å long channel. At the entrance of this channel, on
the surface of the enzyme and approximately 12 Å from the cat-
alytic site, is the inhibitor site [1]. In the T-state, two hydrophobic
residues, Phe285 from the 280s loop, and Tyr613, are stacked
together to form the inhibitor site. The inhibitor site shows great
binding diversity, but it mainly binds purines, ﬂavonoids, and their
derivatives such as IMP, ATP, NADH, FMN and FAD [1–4]. A ligand,
on binding at this site, stabilizes the T-state conformation and
Table 1
The chemical structures of inhibitors known to bind at the GP inhibitor site together
with their Ki’s for GPb inhibition.








Summary of the diffraction data processing and reﬁnement statistics for the GPb
complexes.
GPb complex Ellagic acid Gallic acid
Data collection and processing statistics
Resolution (Å) 38.35–2.00 86.36–2.10
Outermost shell (Å) 2.11–2.00 2.21–2.10
Reﬂections measured 217233 (31425) 375790 (55894)
Unique reﬂectionsa 63707 (9384) 56323 (8072)
Multiplicitya 3.4 (3.3) 6.7 (6.9)
Rsymm
a 0.100 (0.430) 0.077 (0.497)
Completeness (%)a 97.2 (98.8) 98.4 (97.8)
<I/rI>a 5.6 (2.7) 15.4 (5.1)
Reﬁnement statistics
Rcryst
a 0.173 (0.251) 0.159 (0.215)
Rfree
a 0.202 (0.291) 0.189 (0.219)
No of solvent molecules 364 221
r.m.s. deviation from ideality
In bond lengths (Å) 0.009 0.009
In angles () 1.3 1.4
Average B factor (Å2)
Protein atoms 29.8 42.3
Solvent molecules 34.3 43.1
Inhibitor atoms 61.2 56.8
PDB entry 4YUA 4Z5X
a Values in parentheses are for the outermost shell.
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to the catalytic site. The physiological signiﬁcance of the inhibitor
site has yet to be established but it may be used by an unidentiﬁed
compound to enhance the effects of the control of liver GP by glu-
cose, possibly in response to insulin [9,10].
In the recent years, GP has been used for the screening of natu-
ral products [4] for the discovery of non-prescription nutraceutical
(or functional food) products that can assist to regulate blood glu-
cose levels in patients with type 2 diabetes [11,12]. Animal studies
in diabetic and non-diabetic rats have suggested that certain indi-
vidual ﬂavonoids and ﬂavonoid-containing seed extracts have a
hypoglycemic effect due to their effect on glycogen metabolism
[13–15]. The inhibitory potency of common natural ﬂavonoids on
the activity of GP has been examined and showed that certain ﬂa-
vonoids are potent inhibitors of the enzyme [16]. However, the
molecular basis of their inhibitory potency has not yet been estab-
lished. Flavopiridol (Table 1), a synthetic ﬂavonoid has been shown
to potently inhibit GP in vitro (Ki = 1.2 lM) and ex vivo [17] by
binding to the inhibitor site of the enzyme [18]. Likewise, four ole-
ﬁn derivatives of ﬂavopiridol are some of the most potent inhibi-
tors of GPb in vitro (Ki = 1–1.9 lM) and ex vivo and they also
bind to the inhibitor site [17]. Chrysin (Table 1), a natural occurring
ﬂavonoid, is a potent inhibitor (Ki = 19 lM) that also binds to the
inhibitor site [19], while another ﬂavonoid inhibitor, querc-
etagetin, binds to the allosteric site [20]. A recent screening of thir-
teen polyphenolic extracts obtained from the viniﬁcation
byproducts of Vitis vinifera against GP revealed that the most active
ingredient of these extracts is quercetin which binds to a novel
binding site, distinct from the other known sites of the enzyme
[7]. One of the most potent natural ﬂavonoid inhibitors of GP is
ellagic acid with an IC50 value of 3.2 lM [20]. However, currentlyno information about the binding mode of this ligand exists which
would facilitate structure-based inhibitor design and optimization
efforts. Since natural ﬂavonoids are potent inhibitors of GP that
display potency also at the cellular level it is of signiﬁcant interest
to elucidate the molecular details that govern their inhibitory
potency. Thus, we have studied in detail the binding of gallic acid
and its dimer ellagic acid (both natural compounds) to GP by kinet-
ics and X-ray crystallography methods.
2. Materials and methods
Ellagic and gallic acid were purchased from Sigma–Aldrich.
Rabbit skeletal muscle glycogen phosphorylase b (GPb) was iso-
lated, and puriﬁed as described previously [21]. GPa was prepared
from GPb by phosphorylation with a truncated form of the c (cat-
alytic) subunit of rabbit skeletal muscle phosphorylase kinase pro-
duced as described previously [22]. Kinetic studies were performed
at 30 C in the direction of glycogen synthesis by measuring the
inorganic phosphate released in the reaction [21]. Brieﬂy, the
enzyme (5 lg/ml) was assayed in a 30 mM imidazole/HCl buffer
(pH 6.8) containing 60 mM KCl, 0.6 mM EDTA, and 0.6 mM dithio-
threitol using constant concentrations of glycogen (0.2% w/v),
AMP (1 mM), and various concentrations of Glc-1-P and inhibitors.
Initial velocities were calculated from the pseudo-ﬁrst order rate
constants. Kinetic data presented in the form of a Lineweaver–
Burk, Dixon or Hill plots were analyzed for the calculation of the
kinetic and binding parameters by the non-linear regression pro-
gram GRAFIT [23]. GPb crystals were grown in the tetragonal lat-
tice, space group P43212, as described previously [24]. X-ray
crystallography studies were performed by diffusion of a 100 mM
solution of gallic acid or 10 mM of ellagic acid in the crystallization
media (supplemented with 15% (v/v) DMSO in the case of ellagic
acid) in preformed GPb crystals at room temperature for 12 h prior
to data collection. X-ray diffraction data were collected using syn-
chrotron radiation for the GPb-ellagic acid complex on station
ID911-2 at MAX-Lab Synchrotron Radiation Source in Lund,
Sweden. For the GPb-gallic acid complex datawere collected on sta-
tion P14 of the EMBL – Hamburg outstation. Crystal orientation,
integration of reﬂections, inter-frame scaling, partial reﬂection
summation, and data reduction was performed by the program
Mosﬂm [25] for the GPb-ellagic acid complex and XDS [26] for
Fig. 1. Competition of gallic (A) or ellagic acid (B) inhibition and caffeine. Dixon
plots for GPb at constant concentrations of Glc-1-P (20 mM), AMP (1.0 mM) and
glycogen (0.2%) and various concentrations of inhibitors. Caffeine concentrations
were as follows: 0.1 mM (j), 0.2 mM (h), 0.4 mM (N) and 0.8 mM (O).
Fig. 2. The lack of competition between gallic (A) or ellagic acid (B) and AMP.
Inhibition of GPb was measured in at constant concentrations of Glc-1-P (2.5 mM),
and glycogen (0.2%) and various concentrations of AMP. AMP concentrations were
as follows: 0.1 mM (d), 0.2 mM (s), and 1.0 mM (j) in the Dixon plot for gallic acid
(A) and 50 lM (d), 100 lM (s) and 200 lM (j) for the plot of ellagic acid (B).
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were performed by SCALA [27]. Crystallographic reﬁnement of the
complexes was performed by maximum-likelihood methods using
REFMAC [27]. The starting model employed for the reﬁnement of
the complexes was the structure of the native T state GPb complex
determined at 1.9 Å resolution (Leonidas et al., unpublished
results). Ligandmolecule coordinates and topologies were obtained
from the REFMAC library and they were ﬁtted to the electron den-
sity maps after adjustment of their torsion angles. Alternate cycles
of manual rebuilding with the molecular graphic program COOT
[27] and reﬁnement with REFMAC [28] improved the quality of
the models. A summary of the data processing and reﬁnement
statistics for the inhibitor complex structures is given in Table 2.
The stereochemistry of the protein residues was validated by
MolProbity [29]. Hydrogen bonds and van der Waals interactions
were calculated with the program CONTACT as implemented in
CCP4 [27] applying a distance cut off 3.3 Å and 4.0 Å, respectively.
Figures were prepared with PyMol [30]. The coordinates of the
new structures have been deposited with the RCSB Protein Data
Bank (http://www.rcsb.org/pdb) with codes presented in Table 2.
3. Results and discussion
3.1. Determination of inhibition constants (Ki)
Although the target enzyme is the human liver GP, our studies
were performed with the rabbit muscle isoform. However, theinhibitor site is identically conserved in all mammalian GPs [31],
indicating that compounds inhibiting muscle GP by binding at this
site are likely to inhibit also liver GP. Both gallic and ellagic acid are
competitive inhibitors with respect to Glc-1-P as revealed by the
Lineweaver–Burk plots that intersect at the same point on the
y-axis for GPb and GPa. The Ki values derived from the Dixon plots
(1/v vs [I]) were for gallic acid 1.73 ± 0.16 mM and 3.86 ± 0.27 mM
for GPb and GPa, respectively. For ellagic acid they were found to
be 13.4 ± 1.2 lM and 7.52 ± 0.36 lM for GPb and GPa, respectively.
Inhibition constants for ellagic acid are an order of magnitude
lower than those of gallic acid. Although the Ki value for ellagic acid
is similar to that of chrysin (Ki = 19 lM) [19], it remains 10-fold
higher than that of ﬂavopiridol (Ki = 1.2 lM) [19]. Gallic acid
appears to be a poor inhibitor of both enzyme forms since its Ki val-
ues are signiﬁcantly higher than those of caffeine (0.13 mM and
0.17 mM for GPb and GPa, respectively [32]). The Ki values for ella-
gic acid are in good agreement with the IC50 values measured in a
previous study [16] (12.1 lM and 3.2 lM for GPb and GPa, respec-
tively). Furthermore, in agreement with our studies which show
that gallic acid displays Ki values in the range of mM in that study
[16] gallic acid did not show any inhibition of both enzyme forms
in concentrations up to 50 lM.
3.2. Multiple inhibition studies
Caffeine and AMP are two GP ligands that bind to the inhibitor
and to the allosteric sites of GP, respectively [1]. To establish
Fig. 3. Inhibition of GPb by mixtures of gallic (A) or ellagic (B) acid and glucose. (A)
Dixon plot of reciprocal velocity versus glucose concentrations at different gallic
acid concentrations and constant concentrations of Glc-1-P (20 mM), AMP (1 mM),
and glycogen (0.2%). Gallic acid concentrations were 0 (s), 0.5 (d), 1 (h), 2 (j), and
4 mM (4). The replot of the slopes versus gallic acid concentration shown in the
inset yields aKgal, the dissociation constant for gallic acid in the presence of glucose.
Assuming Kgal = 1.73, then a = 1.0. (B) as in (A) except that the concentration of
ellagic acid were 0 (s), 5 (d), 7 (h), 12 (j), and 15 lM (4). The replot of the slopes
versus ellagic acid concentration shown in the inset treated as in (A) yields an
interaction constant, a = 0.22.
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inhibitor binding site, the inhibition behavior of both compounds
was investigated with respect to caffeine and AMP. The kinetic data
were analyzed by Dixon plots from which the interaction constant
(a) between multiple inhibitors can be estimated [33]. Thus, with
varying concentrations of caffeine and ellagic or gallic acids, and
constant concentrations of AMP (1 mM) and substrate (Glc-1-P;
20 mM) the Dixon plots for both GPb (Fig. 1) and GPa, yielded a
pattern of parallel lines (interaction constant approaches inﬁnity),
indicating that the binding of ellagic or gallic acid and caffeine is
mutually exclusive (they compete for the same binding site) [33].
Similar analysis with varying concentrations of AMP and constant
concentrations of substrate (Glc-1-P; 2.5 mM) yielded intersected
lines in the Dixon plots for both GPb (Fig. 2) and GPa, signifying
that gallic or ellagic acids and AMP are not mutually exclusive
(they can both bind at the enzyme) [33]. These experiments indi-
cated that gallic and ellagic acids bind to the inhibitor binding site.
Caffeine functions with glucose (the physiological inhibitor of
the enzyme) in a strongly synergistic mode [34] with an interac-
tion constant a = 0.2. Thus, we investigated whether the bindingof gallic or ellagic acid to GPb interacts with that of glucose. We
carried out initial velocity studies by varying gallic acid, ellagic
acid, and glucose concentrations at ﬁxed concentrations of the sub-
strates Glc-1-P (2.5 mM) and glycogen (0.2%). The results are
shown in Fig. 3. The degree of synergism with glucose differs sig-
niﬁcantly between the two compounds. The binding of gallic acid
does not interact with glucose binding (a = 1.0), while the binding
of ellagic acid is strongly synergistic with that of glucose (a = 0.22).
Thus, only inhibition of ellagic acid is synergistic with glucose. This
means that ellagic acid and glucose are able to bind to the enzyme
at the same time [33], and each compound promotes the binding of
the other, like caffeine and glucose [34]. The effect of glucose on
the potency of ellagic acid could be an important physiological fea-
ture for a liver GPa inhibitor, because the decrease in inhibitor
potency as glucose concentrations decrease in vivo should dimin-
ish the risk of hypoglycemia. This has been also suggested for
another pair of a potent inhibitor and glucose [35].
3.3. Structural studies
In order to provide a structural explanation for the gallic and
ellagic acids inhibition of GPb, we have determined the crystal
structures of the GPb-gallic acid and the GPb-ellagic acid com-
plexes by X-ray crystallography at 2.1 and 2.0 Å resolution, respec-
tively. Both inhibitors were found bound to the inhibitor site, in
agreement with the kinetic experiments, and all ligand atoms are
well deﬁned within the electron density maps (Fig. 4). There are
not any signiﬁcant conformational changes of the polypeptide
chain on binding gallic acid or ellagic acid. Superposition of the
native T state GPb structure with the GPb-gallic acid and the
GPb-ellagic acid complex structures over well-deﬁned residues
gave a root-mean-square displacement (r.m.s.d.) of 0.21 and
0.17 Å for Ca atoms for the gallic and ellagic acids protein com-
plexes, respectively. The binding modes of gallic acid and ellagic
acid are similar. The most characteristic feature is the stacking
interactions of the inhibitors with the aromatic side chains of
Phe285 (from the 280s loop) and Tyr613 (Fig. 5A). On binding at
the inhibitor site gallic acid forms a single hydrogen bond interac-
tion with Asn282 side chain atoms and it is involved in water
mediated hydrogen bond interactions with atoms from residues
Asp283, Ile570, Ala 610, and Gly612 (Table 3). Gallic acid and
GPb residues are involved in 58 van der Waals interactions that
mainly involve atoms from Phe285 and Tyr613. The plane of the
gallic acid ring makes an angle of about 10 with the Tyr613 aro-
matic plane lying at distances varied between 3.7 and 4.3 Å, while
it is almost parallel to the plane of the benzyl ring of Phe285, at a
distance of 3.7 Å (Fig. 5A). Ellagic acid on binding to the inhibitor
binding site forms a single strong hydrogen bond to the side chain
atom ND of Asn282 and it is involved in water-mediated hydrogen
bond interactions with atoms from Asp283, Ile570, Ala610, Gly612,
His614, and Met615 (Table 4). The plane of the ellagic acid lies at
distances 3.4 and 3.6 Å from the planes of benzyl ring of Phe285
and Try613, respectively. The ellagic acid plane is parallel to the
plane of the Phe285 phenyl ring and at an angle of 24 from the
plane of the hydroxyphenyl ring of Tyr613 (Fig. 5B). Due to its lar-
ger size, the ellagic acid exploits almost twice the number of van
der Waals interactions with GPb upon binding (95) than the gallic
acid (58). On forming the inhibitor complexes both ligands become
buried. The solvent accessibilities of the free and bound ligand
molecules are 299 and 78 Å2 (gallic acid), and 427 and 116 Å2 (ella-
gic acid), respectively, indicating that 74% of the inhibitor surface
becomes buried. This comes almost entirely from the non-polar
groups. On the protein surface, a total of 669 and 772 Å2 solvent
accessible surface area becomes inaccessible on binding of the gal-
lic and the ellagic acids, respectively. The total buried surface areas
(protein plus ligand) are 371 Å2 and 532 Å2 for the gallic and ellagic
Fig. 4. Stereo diagrams of the sigmaA 2FO  FC electron density map, contoured at 1r, for the bound gallic (A) and ellagic (B) acid at GPb. Electron density maps were
calculated before incorporating the inhibitor molecules in the reﬁnement procedure.
Table 3
Gallic acid interactions with glycogen phosphorylase b residues in the crystal.
Inhibitor atom Protein residues (atoms)
Hydrogen bonds (distance in Å) Van der Waals interactions
CAH Tyr613 (CD1), Phe285 (CE1)
OAA Tyr613 (CE1)
CAK Tyr613 (CD1, CG), Phe285 (CD1, CE1, CZ)
CAF Tyr613 (CD1, CE1, CZ, CE2, CD2, CG), Phe285 (CG, CD1, CE1)
CAG Tyr613 (CB, CG), Phe285 (CD2, CZ, CE2)
CAJ Tyr613 (CB), Phe285 (CG, CD2, CE2)
OAD Water-184 (3.3) Ala610 (CB), Phe285 (CD2), Asn282 (OD1),
CAL Tyr613 (CD2), Ala610 (CB), Phe285 (CB, CG, CD2), Water-31
OAE Asn282 OD1 (3.3), Water-31 (2.4) Asn282 (CA, CB, CG, OD1), Ala610 (CB), Phe285 (CB, CG, CD2)
CAI Tyr613 (CE2, CD2, CG), Phe285 (CB, CG, CD1, CD2), Water-31 (O)
OAC Water-31 (2.7) His571 (NE2, CD2), Asp283 (O), Tyr613 (CE2, CD2), Phe285 (CB, CG)
Total 4 58
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[36], GPb-ﬂavopiridol [36], GPb-CP320626 [37] and GPb-W1807
[38] complexes are 467 Å2, 618 Å2, 819 Å2 and 852 Å2, respectively.
These areas show an approximate correlation with the ligand afﬁn-
ity since they follow the order of potency of the ligands: gallic acid
(Ki = 1.7 mM), caffeine (Ki = 0.13 mM) [32], ellagic acid
(Ki = 13.4 lM), ﬂavopiridol (Ki = 1.2 lM) [19] CP320626
(IC50 = 334 nM) [37] and W1807 (Ki = 1.6 nM) [38].
3.4. Comparison with other ﬂavonoids
The most potent ﬂavonoid inhibitors that bind to the GPb inhi-
bitor site, reported thus far, are ﬂavopiridol (Ki = 1.2 lM) andchrysin (Ki = 19 lM) [19] (Table 1). Although the structural mode
of their binding is very similar, the source of the greater inhibition
of ﬂavopiridol was attributed by QM/MM-PBSA calculations to
favorable interactions of its 4-hydroxypiperidin-1-yl group with
GPb without signiﬁcant desolvation costs [19]. Ellagic acid displays
a better inhibitory potency than chrysin. Comparative structural
analysis of the binding of ellagic acid and ﬂavopiridol to GPb
reveals that although both ligands bind between the benzyl rings
of Phe285 and Tyr613 there are signiﬁcant differences. Thus,
ﬂavopiridol stacks ring A (Table 1) against the phenyl ring of
Phe285 and ring C against the hydroxyl-phenyl ring of Tyr613.
Ellagic acid has its rings B and A co-planar against the aromatic
side chains of Phe285 and Tyr613, respectively. Thus, ﬂavopiridol
Fig. 5. Stereo diagrams of the binding of gallic (A) and ellagic (B) acid to the inhibitor binding site of GPB. Hydrogen bond interactions are represented by dotted lines and
water molecules as black spheres.
Table 4
Ellagic acid interactions with glycogen phosphorylase b residues in the crystal.
Inhibitor atom Protein residues (atoms)
Hydrogen bonds (distance in Å) Van der Waals interactions
C1 Gly612 (C, O), Phe285 (CZ, CE2)
C2 Tyr613 (CB), Phe285 (CG, CD2, CE1, CZ, CE2)
C3 Tyr613 (CG, CD1), Phe285 (CG, CD1, CD2, CE1, CZ, CE2)
C4 Phe285 (CE1, CZ)
O5 Water-227 (3.3) Phe285 (CZ)
C6 Phe285 (CZ), Gly612 (O), Water-227 (O)
C7 Tyr613 (CG, CD1, CE2, CD2), Phe285 (CB, CG, CD1, CE1)
C8 Tyr613 (CD1, CE1, CZ, OH, CE2, CD2), His571:A (NE2), Phe285 (CD1)
C9 Tyr613 (CE1, CZ, OH)
C10 Tyr613 (CE1), Phe285 (CE1)
C11 Ala610 (CB), Tyr613 (CB), Phe285 (CG, CD2, CE2)
O12 Water-33 (3.3) Ala610 (CB), Phe285 (CB, CG, CD2)
C13 Tyr613 (CG, CE2, CD2), Phe285 (CB, CG, CD1), Water-33 (O)
C14 Gly612 (CA, C, O), Phe285 (CE2),
C15 Gly612 (CA, C)
C16 Ala610 (CB), Phe285 (CD2), Asn282:A (ND2)
O20 Tyr613 (CE1, CZ, OH), Glu382 (OE2), His571:A (CE1, NE2), Glu572 (OE2)
O21 Water-33 (2.8) His571:B (CE1), His571:A (CD2, NE2), Asp283 (O), Tyr613 (CE2, CD2), Phe285 (CB, CG)
O22 Asn282 ND (2.2) Ala610 (CB), Asn282:A (CB, CG), Asn282:B (CB, ND2)
O23 Gly612 (CA, N), Asn282:A (ND2), Glu287 (OE2)
O24 Water-227 (3.1) Gly612 (O)
Total 5 95
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Fig. 6. Structural comparison (in stereo) of the GPb-ellagic acid (black) and the GPb-ﬂavopiridol (PDB entry: 1C8K; white) complexes in the vicinity of the inhibitor site.
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Moreover, the planes formed by the aromatic rings of ﬂavopiridol
and ellagic acid are inclined to each other by 15 (Fig. 6).
Flavopiridol being bulkier than ellagic acid exploits 12 additional
van der Waals interactions with the protein. In contrast to ellagic
acid which forms a strong hydrogen bond interaction with
Asn282, ﬂavopiridol does not participate in any direct hydrogen
bond with protein residues. Both ligands are involved in
water-mediated hydrogen bond interactions with GPb. Therefore,
it seems that the difference in the potency between ﬂavopiridol
and ellagic acid might be attributed to the interactions of the
4-hydroxypiperidin-1-yl group of ﬂavopiridol with GPb, like in
the case of chrysin and ﬂavopiridol [19].
Flavonoids are natural abundant compounds found ubiqui-
tously in plants and the most common group of polyphenolic com-
pounds in the human diet. The present study establishes ellagic
acid as the most potent natural compound that binds to the GP
inhibitor site. The inhibitory potency of ellagic acid is even stronger
for GPa than for GPb, and since GPa is the physiologically active
form of the enzyme this fact adds more value to a potential antihy-
perglycaemic usage of ellagic acid. Furthermore, our results can
serve as the starting point for the exploitation of food products that
contain ellagic acid for antidiabetic usage and the development of
novel biofunctional food and dietary supplements/herbal medici-
nes, an increasingly important approach to both diabetes treat-
ment and prevention.
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